COVID vaccines could be available for young children by end of February

What to expect Pfizer and BioNTech are expected to submit a request to the FDA as soon as Tuesday for emergency-use authorization of their COVID vaccine for children 6 months to 5 years old, per WashPost.

• Regulators could then begin reviewing the two-shot data. Data on the effectiveness of a third shot isn't expected until until at least late March.

Zoom in: "The idea is, let’s go ahead and start the review of two doses," a source told WashPost. "If the data holds up in the submission, you could start kids on their primary baseline months earlier than if you don’t do anything until the third-dose data comes in."

• Once the third shot data is available, regulators could then decide whether to authorize a third dose, WashPost writes.

Details: Pfizer announced in December that two shots of the vaccine did not produce an immune response in 2-, 3- and 4-year-olds that is comparable to that of adults, although it did produce an adequate immune response in children between the ages of 6 months and 2 years.

What we're watching: If it comes to fruition, the plan could be a source of relief for parents anxious to get their young children vaccinated.

• On the other hand, the unconventional authorization process could also add to vaccine skepticism, especially as uptake has been low among younger children already eligible for the shots.